Skip to content
Search AI Powered

Latest Stories

What’s Going on with New York’s Legal Cannabis Roll Out? 

What's Going on With New York's Legal Cannabis Rollout
What's Going on With New York's Legal Cannabis Rollout

The New York cannabis industry is facing a complex and challenging landscape as it transitions from a medical marijuana program to a fully legal recreational market. Despite the recent legalization of adult-use cannabis in the state, there are still many issues to be addressed, including regulatory compliance, licensing, distribution, capital and equity concerns, and of course, litigation.

Recently, several lawsuits have been filed against the New York State Cannabis Control Board (CCB) and the Office of Cannabis Management (OCM), which are the agencies responsible for overseeing the state's cannabis industry.


One of the lawsuits filed in late in 2022, was brought forth by Variscite, a company registered under the laws of New York, which applied for a CAURD (Cannabis Control Board Adult-Use Retail Dispensary) license. At issue is the fact that the majority owner of Variscite had a cannabis conviction under Michigan law and no significant connection to New York, Variscite was deemed ineligible for the license. 

Variscite argued in its lawsuit that the New York residency requirement was discriminatory against out-of-state applicants and violated the Dormant Commerce Clause (DCC) implied in the Constitution. A federal judge agreed with Variscite's argument and ruled that the residency requirement did not serve a compelling state policy and, therefore, violated the DCC. During the application process, Variscite selected Brooklyn, Central New York, the Finger Lakes, the Mid-Hudson area, and Western New York as possible regions for licensure. 

Consequently, the judge ruled that New York could not issue CAURD licenses for dispensaries in those regions while the case was pending. This decision is expected to affect around 63 of the 150 CAURD licenses that the Office of Cannabis Management had planned to issue by the end of 2022. However, the ruling did not affect eleven other regions, including the Bronx, Manhattan, Queens, Staten Island, and Long Island.

Another lawsuit was recently filed by a group of larger cannabis companies, including Acreage Holdings, Columbia Care, and Curaleaf and a group of medical cannabis professionals and patients has filed a lawsuit against the state of New York, claiming that the recently passed recreational cannabis law infringes on their right to affordable and accessible medicine. The lawsuit argues that the new law, which allows for the establishment of a recreational cannabis market, will lead to shortages and increased prices for medical cannabis products. The plaintiffs contend that the state is obligated to ensure a steady supply of affordable medical cannabis products for patients, and that the new law fails to meet that obligation. 

The case highlights the challenges of balancing the needs of medical cannabis patients with the desire to establish a thriving recreational market, as more states move to legalize cannabis for both medical and recreational use.

The lawsuits come at a time when the state is still developing and finalizing its regulations for the new adult-use cannabis market. The OCM recently released its proposed rules for the industry, which include provisions aimed at promoting social equity and ensuring that small businesses have a fair shot at participating in the market.

Despite all these efforts, many stakeholders in the cannabis industry are concerned about the potential for large, out-of-state operators to dominate the market and squeeze out smaller, less capitalized local upstart businesses before they get a chance to get off the ground. They are also worried about the potential for regulatory overreach and heavy-handed enforcement.

As the state moves forward with the implementation of its new recreational cannabis market, it will need to address these and a host of other concerns in order to create a fair and equitable industry that benefits all stakeholders, from large corporations to small businesses and individual consumers. 

The lawsuits filed against the CCB and OCM are just one indication of the complex and challenging landscape that lies ahead for New York's nascent legal cannabis industry.

And, the response from across the New York cannabis industry has been mixed. Some industry leaders argue that the lawsuits are misguided and that the new laws will ultimately benefit medical cannabis patients by increasing overall demand for cannabis products and driving down prices. Others, however, acknowledge that there may be some short-term disruptions as the recreational market ramps up, and they urge the state government to take steps to ensure that medical cannabis patients are not unduly affected.

Overall, the lawsuits highlight the complex and sometimes competing interests at play in the expanding cannabis industry, as well as the challenges of balancing the needs of medical cannabis patients with the desire to establish a thriving recreational market and those interested in building an equitable and fair industry for those communities most directly impacted by the war on drugs. 

As more states legalize cannabis for both medical and recreational use, similar issues are likely to arise, and policymakers will need to not only carefully consider the impact of their decisions on all stakeholders involved, but to actually invest the time and resources in listening to each of these stakeholders and involving them in decision making process. 

Overall, the development of NY’s nascent cannbis market to a mature cannabis market is going to be a complex and dynamic process that will require careful attention to changing market conditions, industry, consumer and patient needs and regulatory requirements. 

We have to remember that we are still in the first inning of this and we will see NY’s legal cannabis industry thriving in the coming months, lawsuits and all. We’re NYers after all and we don’t let much, if anything, stand in our way. 

As Alicia Keys so soulfully sings: 

Even if it ain't all it seems

We got a pocketful of dreams 

Baby, we’re from New York

Concrete jungle where dreams are made of

There's nothin' we can't do

Now, we’re in New York

These streets will make us feel brand-new

Now, let’s hear it for New York, New York, New York

More For You

Traveling with cannabis? Read this article first.
Traveling with cannabis? Read this article first.

Cannabis and New York Airports? Here’s What Travelers Need To Know

Flying out of New York with your personal cannabis stash? Relax.

According to an article published by the Times Union, New York airport security checkpoints are no longer seizing cannabis.

Keep ReadingShow less
Union Square Travel Agency: A Cannabis Store (USQTA)
Union Square Travel Agency: A Cannabis Store (USQTA)
Will Ellis

Union Square Travel Agency: Where Wanderlust Meets the Enchantment of Cannabis

Come fly with me, let's fly, let's fly away
If you can use some exotic weed
There's a new dispensary on Broadway
Come on, fly with me, we'll float down in the blue…

Frank Sinatra

Union Square Travel Agency: A Cannabis Store (USQTA) is poised to revolutionize the cannabis dispensary experience in New York City with its expansion to a new 2800-square-foot permanent space located at 835 Broadway at 13th St., one block south of Union Square. 

Keep ReadingShow less
Frenchy holding a giant hashish temple ball.
Frenchy holding a giant hashish temple ball.
Image from frenchycannoli.com

Hashish Legend Frenchy Cannoli Has Passed Away: 1956-2021

The sun came up less one ray on Monday morning after the untimely passing of Frenchy Cannoli, Master Hashishin.

Cannoli passed away on Sunday, July 18, 2021, due to complications from surgery, according to his wife Madame Cannoli in a note to cannabis community friends and loved ones.

Keep ReadingShow less
Drug Enforcement Administration (DEA) stance on Delta-8 THC Stirs Controversy
Drug Enforcement Administration (DEA) stance on Delta-8 THC Stirs Controversy

The Controversy Surrounding Delta-8 THC: Legal or Prohibited Substance?

In the wake of the rapid expansion of the hemp industry and the increasing popularity of CBD products, a new cannabinoid has emerged on the market—delta-8 THC. While its popularity has been on the rise, so has the confusion and debate over its legality. 

A recent revelation from a Drug Enforcement Administration (DEA) official has shed light on the agency's stance on Delta-8 THC, sparking discussions about its classification and implications for the industry.

Keep ReadingShow less
Talking Joints Memo - Chris Faraone
Talking Joints Memo - Chris Faraone

Massachusetts State Lawmakers Release Scathing Critique of MA's Cannabis Control Commission

By Chris Faraone, Talking Joints Memo. Reprinted with permission from Talking Joints Memo. .

“The public deserves some accountability on why these issues have proven so hard to stamp out, and what long-term changes the agency is making to get its work done with more transparency and efficiency.”

There has been endless drama around the Massachusetts Cannabis Control Commission over the past few months, all of which is only heightening in the wake of state Treasurer Deb Goldberg suspending the agency’s chairwoman last week.

Keep ReadingShow less